Stephen P. Carey, Senior Vice President and Chief Financial Officer of ANI Pharmaceuticals Inc., sold 2,850 shares of common stock on August 31, 2026, for a total of $207,480 at prices ranging from $71.89 to $73.36 per share.
The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026. Carey retained 171,843 shares of common stock in the company following the sale.
ANI Pharmaceuticals reported adjusted earnings of $2.21 per share for the second quarter of 2026, exceeding Wall Street expectations of $2.03. Revenue for the quarter reached a record $266 million, topping forecasts of $262.14 million.
Full-year guidance for Cortrophin was reduced by $20 million to $25 million due to first-half underperformance, though total net revenue, EBITDA, and earnings per share guidance for 2026 was maintained. The company noted growth in its Generics and Brand Royalties and Other Revenues segments.
Analysts maintained mixed ratings: Guggenheim kept its Buy rating but lowered its price target from $124 to $119, while Canaccord Genuity retained its Hold rating and trimmed its target from $91 to $90.
